Prostate Cancer
Conditions
Interventions
Index test:mpMRI
PET/CT
Sponsors
The Second Hospital of Tianjin Medical University
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: experience group: 1. Patients whose Gleason score was more than or equal to 7 and who underwent radical surgery after preoperative neoadjuvant therapy; 2. Patients whose specimens can be stained by immunohistochemistry related to CRPC molecular typing; 3. Patients who received MD mpmri and 68Ga PSMA PET / CT within one month before operation; 4. Patients who have signed the agreement of specimen donation after operation and whose specimens are qualified for making large pathological sections; 5. Patients without contraindications of MRI and PET examination (including no serious cardiovascular disease, no metal implants, etc.). Validation group: (1) Confirmed CRPC patients; (2) The patients were examined with MD mpmri and 68Ga PSMA PET / CT within 1 month; (3) All patients received a second prostate puncture; (4) The results of puncture can be stained by immunohistochemistry; (5) Patients without contraindications of MRI and PET examination (including no serious cardiovascular disease, no metal implants, etc.); (6) Patients without contraindications of biopsy (such as normal coagulation function, no acute infection, etc.).
Exclusion criteria
Exclusion criteria: experience group: 1. Patients with non Gleason score greater than 7 and without neoadjuvant therapy have surgical indications; 2. After adjunctive treatment, the tumor did not shrink, but increased; 3. After adjuvant therapy for prostate cancer, the tumor did not shrink or grow; the experimental group was unable to complete the DC chemotherapy cycle due to failure of treatment and serious side effects; 4. Patients who had contraindications to PET / CT and MRI contrast media and could not complete follow-up review; 5. Patients who are known to be allergic to any of the contrast agents used in this study; 6. Patients with contraindications for prednisone use, such as active infection, active peptic ulcer, recent gastrointestinal anastomosis, fracture, wound healing, corneal ulcer, severe osteoporosis or other diseases, or patients with systemic steroids (i.e. more than 10 years old) Prednisone (mg / D) or other corticosteroids of the same pharmacophysiological dose; 7. Patients with any of the following conditions within 6 months before enrollment: stroke, myocardial infarction, severe / unstable angina pectoris, coronary artery / peripheral artery bypass grafting, congestive heart failure (New York Heart Association grade III or IV); 8. Active viral hepatitis, known human immunodeficiency virus infection with detectable viral load, or chronic liver disease requiring treatment; 9. Any other serious or unstable disease or medical, social or psychological condition that may endanger the safety of the subjects and / or affect their compliance with the test procedures, or may prevent the subjects from participating in the study or evaluating the results of the study; 10. Patients with claustrophobia and pacemaker; 11. Patients unable to swallow oral drugs. Validation group: 1. Patients with non metastatic, non neuroendocrine hormone resistant prostate cancer; 2. Patients who had contraindications to PET / CT and MRI contrast media and could not complete follow-up review; 3. Patients whose secondary pathological puncture results could not be judged by molecular typing; 4. Due to the progress of the disease, the patients can not continue to complete the puncture or PET / CT and MRI examination or injection of contrast agent; 5. Patients who are known to be allergic to any of the contrast agents used in this study; 6. Patients with contraindications for prednisone use, such as active infection, active peptic ulcer, recent gastrointestinal anastomosis, fracture, wound healing, corneal ulcer, severe osteoporosis or other diseases, or patients with systemic steroids (i.e. more than 10 years old) Prednisone (mg / D) or other corticosteroids of the same pharmacophysiological dose; 7. Patients with any of the following conditions within 6 months before enrollment: stroke, myocardial infarction, severe / unstable angina pectoris, coronary artery / peripheral artery bypass grafting, congestive heart failure (New York Heart Association grade III or IV); 8. Active viral hepatitis, known human immunodeficiency virus infection with detectable viral load, or chronic liver disease requiring treatment; 9. Any other serious or unstable disease or medical, social or psychological condition that may endanger the safety of the subjects and / or affect their compliance with the test procedures, or may prevent the subjects from participating in the study or evaluating the results of the study; 10. Patients with claustrophobia and pacemaker; 11
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Molecular typing of prostate cancer;Multiparameter MRI;PET/CT; | — |
Countries
China
Contacts
Public ContactZhao Yang
The Second Hospital of Tianjin Medical University
Outcome results
None listed